Complete hepatic resection of metastases from leiomyosarcoma prolongs survival

Chen, Herbert; Pruitt, Anita; Nicol, Theresa L.; Gorgulu, Semih; Choti, Michael A.

doi:10.1016/s1091-255x(98)80006-1

Cited by 93 publications

(75 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, two studies reported the effect of surgery on metastatic disease. 50,55 The results (Tables 10 and 11) observed in these intervention studies in general did not promise patient benefit. Seven studies reported median survival (range 8-24 months).…”

Section: Results Reported In Studies Of Alternative Treatmentsmentioning

confidence: 90%

See 1 more Smart Citation

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

Wilson

Connock²,

Song³

et al. 2005

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: D Peake has been paid by Novartis to give one lecture on GIST and was sponsored to attend the Third International Symposium on GIST. Other than this, members of the review team at the University of Birmingham have no any pecuniary relationship with sponsors, specific or non-specific. J Raftery is Director of the NCCHTA but he was not involved in the editorial process for this report. HTA Published July 2005This report should be referenced as follows: NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technolo...

show abstract

Section: Results Reported In Studies Of Alternative Treatmentsmentioning

confidence: 90%

“…Fifteen studies 18,[46][47][48][49][50][51][52][53][54][55][56][57][58] were included (of which nine were trials, one controlled) that reported on treatments other than imatinib for advanced GIST. In only one small study was cKIT status analysed (retrospectively, by Ryan and co-workers 46 ).…”

Section: Results Reported In Studies Of Alternative Treatmentsmentioning

confidence: 99%

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

Wilson

Connock²,

Song³

et al. 2005

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…SCS for patients who have pulmonary recurrent disease has been reported to lead to improved survival, particularly in those with unilateral disease, a smaller number of resected metastases (<3), a smaller tumor (<3 cm) and a longer DFI (<6, or 12 months) (8)(9)(10). However, studies on SCS for extra-pulmonary recurrences of uterine sarcomas are limited, and have only small sample sizes (4,11,(14)(15)(16)(17). Leitao et al (14) reported that optimal surgical resection may improve the survival of patients with either pulmonary or extra-pulmonary metastases, after retrospectively surveying 41 patients with recurrent LMS (including 28 patients who had non-thoracic recurrences).…”

Section: Discussionmentioning

confidence: 99%

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

et al. 2018

View full text Add to dashboard Cite

Abstract. Uterine sarcomas are some of the most malignant and aggressive tumor types among the gynecologic malignancies, and they are associated with a high rate of recurrence and a poor prognosis. Due to their rarity and diversity, the optimal treatment for recurrent uterine sarcomas has not yet been elucidated. The aim of the present study was to investigate the potential of secondary cytoreductive surgery (SCS) for patients with recurrent uterine sarcomas. A total of 18 patients with recurrent uterine sarcomas were retrospectively identified at the

show abstract

“…There is some evidence that metastatectomy can improve survival in selected patients (Chen et al 1998). Those that benefi t most have a disease free interval of greater than 12 months, well differentiated histology and an isolated liver metastasis.…”

Section: Surgerymentioning

confidence: 99%

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

Din

Woll²

2008

TCRM

View full text Add to dashboard Cite

Abstract:Gastrointestinal stromal tumor (GIST) is a rare primary neoplasm of the gastrointestinal tract, mesentery, or omentum. In the past, surgery has been the only effective treatment. The diagnosis and treatment of GIST has been revolutionized over the past decade, since expression of the receptor tyrosine kinase KIT was shown to occur on these tumors. Mutations in this proto-oncogene commonly cause constitutive activation of the KIT tyrosine kinase receptor, an important factor in the pathogenesis of the disease. The development of specifi c tyrosine kinase inhibitors, such as imatinib mesylate, has led to a breakthrough in the treatment of advanced GIST. Treatment with this drug has led to signifi cant improvements in survival, with overall response rates in excess of 80%. Side effects are common, but usually manageable. The success of this drug has led to further trials investigating its use in the pre-and postoperative situation. This review summarizes the current knowledge of GIST and imatinib treatment and possible future developments.

show abstract

Complete hepatic resection of metastases from leiomyosarcoma prolongs survival

Cited by 93 publications

References 13 publications

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

Contact Info

Product

Resources

About